Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
117M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
49.1M
-
Shares change
-
+2.29M
-
Total reported value, excl. options
-
$432M
-
Value change
-
+$14.8M
-
Put/Call ratio
-
0.97
-
Number of buys
-
48
-
Number of sells
-
-38
-
Price
-
$8.80
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q4 2017
115 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q4 2017.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.1M shares
of 117M outstanding shares and own 41.98% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.26M shares), FMR LLC (6.68M shares), Temasek Holdings (Private) Ltd (6.56M shares), BlackRock Inc. (3.2M shares), Kohlberg Kravis Roberts & Co. L.P. (3.06M shares), STATE STREET CORP (2.1M shares), JPMORGAN CHASE & CO (1.92M shares), Vanguard Group Inc (1.88M shares), CITADEL ADVISORS LLC (1.77M shares), and ORBIMED ADVISORS LLC (1.47M shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.